Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Murase N et al. | Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. | 1993 | Transplant. Proc. | pmid:7679817 |
Schreier MH et al. | Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? | 1993 | Transplant. Proc. | pmid:7679818 |
Kahan BD | Cyclosporine: the base for immunosuppressive therapy--present and future. | 1993 | Transplant. Proc. | pmid:7679819 |
Starzl TE | FK 506 versus cyclosporine. | 1993 | Transplant. Proc. | pmid:7679820 |
Nakajima K et al. | Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. | 1993 | Transplant. Proc. | pmid:7679821 |
Todo S et al. | Intestinal transplantation in humans under FK 506. | 1993 | Transplant. Proc. | pmid:7680148 |
Reyes J et al. | Nutritional management of intestinal transplant recipients. | 1993 | Transplant. Proc. | pmid:7680149 |
Abu-Elmagd KM et al. | Monitoring and treatment of intestinal allograft rejection in humans. | 1993 | Transplant. Proc. | pmid:7680150 |
McCauley J et al. | FK 506 in the management of nephrotic syndrome after renal transplantation. | 1993 | Transplant. Proc. | pmid:7680154 |
Mañez R et al. | Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. | 1993 | Transplant. Proc. | pmid:7680170 |
Müller MK et al. | [Pathophysiologic concepts and protective possibilities in experimental pancreatic lesions]. | 1993 | Z Gastroenterol | pmid:7504856 |
Panis Y and Valleur P | [Small intestine transplantation. Experimental and clinical results]. | 1993 | Ann Chir | pmid:7504899 |
Tsai M et al. | Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. | 1993 | Eur. J. Immunol. | pmid:7504992 |
Hendrickson BA et al. | Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. | 1993 | Gene | pmid:7505249 |
Lundemose AG et al. | Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. | 1993 | Mol. Microbiol. | pmid:7682281 |
Wiesner RH et al. | Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. | 1993 | Transplant. Proc. | pmid:7682352 |
Frank B et al. | Neurotoxicity of FK 506 in liver transplant recipients. | 1993 | Transplant. Proc. | pmid:7682355 |
Klintmalm GB et al. | Rejection: FK 506 for rescue or maintenance. | 1993 | Transplant. Proc. | pmid:7682356 |
Woodle ES et al. | Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. | 1993 | Transplant. Proc. | pmid:7682358 |
McDiarmid SV et al. | FK506 conversion for intractable rejection of the liver allograft. | 1993 | Transpl. Int. | pmid:7507675 |
Tokunaga Y et al. | Living related liver transplantation across ABO blood groups with FK506 and OKT3. | 1993 | Transpl. Int. | pmid:7507676 |
Winkler M et al. | Conversion from cyclosporin to FK 506 after liver transplantation. | 1993 | Transpl. Int. | pmid:7507677 |
David M et al. | [Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy]. | 1993 | Zentralbl Gynakol | pmid:7692689 |
Wallemacq PE and Reding R | FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. | 1993 | Clin. Chem. | pmid:7693372 |
Nakamura T et al. | Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. | 1993 | EMBO J. | pmid:7693452 |
Higa A et al. | Attenuation of epithelial injury in acute experimental colitis by immunomodulators. | 1993 | Eur. J. Pharmacol. | pmid:7693488 |
Schmitt J et al. | Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. | 1993 | Gene | pmid:7693550 |
Yatscoff RW et al. | Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro. | 1993 | Clin. Biochem. | pmid:7507804 |
Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
Wiederrecht G et al. | The mechanism of action of FK-506 and cyclosporin A. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509138 |
Morikawa K et al. | Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:7509146 |
Schwaninger M et al. | The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line. | 1993 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:7509460 |
Shapiro R et al. | FK 506 interaction with danazol. | 1993 | Lancet | pmid:7684106 |
Becker JW et al. | FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. | 1993 | J. Biol. Chem. | pmid:7684380 |
Dickey JB et al. | Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. | 1993 | Cornea | pmid:7684663 |
Francavilla A et al. | Hepatic regeneration and growth factors. | 1993 | J Surg Oncol Suppl | pmid:7684910 |
Connelly PR et al. | Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. | 1993 | Biochemistry | pmid:7684925 |
Thomson AW et al. | FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. | 1993 | Springer Semin. Immunopathol. | pmid:7686690 |
Koga T et al. | Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. | 1993 | Chest | pmid:7686837 |
Nishi M et al. | Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. | 1993 | Invest. Ophthalmol. Vis. Sci. | pmid:7686893 |
Nishizawa S et al. | Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. | 1993 | Neurosurgery | pmid:7687044 |
Odocha O et al. | Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. | 1993 | Transplant. Proc. | pmid:7689269 |
McCauley J et al. | Renal transplantation under FK 506 in African-Americans: early experience. | 1993 | Transplant. Proc. | pmid:7689270 |
Groth CG et al. | New immunosuppressive drugs in transplantation. | 1993 | Transplant. Proc. | pmid:7689274 |
McMaster P and Buist L | FK 506 in transplantation. | 1993 | Transplant. Proc. | pmid:7689275 |
Jost U et al. | FK 506 treatment of intractable rejection after liver transplantation. | 1993 | Transplant. Proc. | pmid:7689276 |
Hacker J and Fischer G | Immunophilins: structure-function relationship and possible role in microbial pathogenicity. | 1993 | Mol. Microbiol. | pmid:7526121 |
Olivera DL et al. | Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. | 1993 | Clin. Immunol. Immunopathol. | pmid:7690317 |
Whitington PF et al. | Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. | 1993 | Lancet | pmid:7690444 |
Takahashi H and Iizuka H | Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation. | 1993 | J. Dermatol. Sci. | pmid:7511000 |